Missoula, MT — October 1st, 2025 — Inimmune, a biotechnology company pioneering novel vaccine adjuvants, immunotherapies, and delivery systems, announced today that its leadership team will deliver multiple presentations at the World Vaccine Congress (WVC) in Amsterdam, Netherlands, October 13–16, 2025.
David Burkhart, Ph.D., CEO of Inimmune, will speak at the Vaccine Delivery Workshop on October 13. His presentation, titled “Development of next generation adjuvant systems for mucosal vaccine delivery”, will highlight advances in adjuvant development and delivery technologies supporting next-generation vaccines.
On October 14, Shannon Miller, Ph.D., VP of Operations, will join the panel discussion “Applications of Novel Adjuvants in Combating Emerging Pathogens and Integration into Next-Generation Vaccine Design.”
On October 15, Juhienah Khalaf, Ph.D., Director of Chemistry, will co-present with Dr. Peter Tygesen, Business Development Director at SPI Pharma, in the session Innovative Adjuvants for Accessible Global Health. Their talk, “Innovative Adjuvants for Global Health, Now Available for Licensing,” will highlight Inimmune’s collaborative efforts to deliver affordable and accessible adjuvant systems.
Inimmune’s presentations will feature recent progress across its pipeline of immunomodulators and adjuvant platforms. The company prioritizes research into new classes of adjuvants and immunotherapies for both vaccines and stand-alone indications and has a deep pipeline of rapidly advancing programs.
“Inimmune is proud to join global leaders at this year’s World Vaccine Congress,” said Dr. Burkhart. “We’re excited to share our latest advancements in adjuvant and delivery system development, designed to tailor immune responses and accelerate vaccine innovation. This congress is an ideal platform to showcase our pipeline and explore new partnerships.”
The company recently completed a Phase 1a/1b trial of INI-2004, a TLR4 agonist for allergic rhinitis, with a Phase 2 study expected to launch in Q1 2026. Inimmune is also advancing INI-4001, a TLR7/8 agonist, which is currently in a Phase 1 oncology trial.
The World Vaccine Congress is Europe’s leading vaccine event, bringing together experts from industry, academia, and government to advance research in vaccine development, delivery, and immunology, with a focus on global health and pandemic preparedness.
